Real-world study of the multimorbidity and health service utilisation among individuals with non-diabetic hyperglycemia and type 2 diabetes mellitus in North West London
Authors:
- Rakesh DattaniRDRakesh Dattani
- Zia Ul-HaqZUZia Ul-Haq
- Moulesh ShahMSMoulesh Shah
- Tahereh KamalatiTKTahereh Kamalati
- Benjamin PierceBPBenjamin Pierce
- Amanda LucasALAmanda Lucas
- Ahmed BaruwaABAhmed Baruwa
- Livi Bickford-SmithLBLivi Bickford-Smith
- Jack ChilcottJCJack Chilcott
- Thomas GriffithsTGThomas Griffiths
- Andrew Howard FrankelAFAndrew Howard Frankel
- Tony WillisTWTony Willis
Open Access
- 8 August 2024
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (4) , e003873
Abstract
Introduction The prevalence of non-diabetic hyperglycemia (NDH) and type 2 diabetes mellitus (T2DM) is increasing. While T2DM is recognised to be associated with multimorbidity and early mortality, people with NDH are frequently thought to be devoid of such complications, potentially exposing individuals with NDH to suboptimal care. We therefore used the Discover London Secure Data Environment (SDE) dataset to appreciate the relationship of NDH/T2DM with multimorbidity, healthcare usage, and clinical outcomes. Research design and methods The dataset was retrospectively analysed between January 1, 2015 and December 31, 2020 to understand the relationship between NDH/T2DM and multimorbidity primary/secondary healthcare usage and clinical outcomes. This was compared with a cohort of individuals with thyroid disease but no NDH/T2DM. Results The dataset identified 152,384 and 124,190 adults with NDH and T2DM compared with 11,626 individuals with thyroid disease (control group). Individuals with NDH and individuals with T2DM had a high burden of disease, with only 13.1% of individuals with either NDH or T2DM not found to be suffering from at least one of the disease states of interest. The three most common comorbidities experienced by individuals with NDH were hypertension (41.4%), hypercholesterolemia (37.5%), and obesity (29.8%) compared with retinopathy (68.7%), hypertension (59.4%), and obesity (45.8%) in individuals with T2DM. Comparatively, the most common comorbidities in the control group were depression (30.8%), hypercholesterolemia (24.4%), and hypertension (17.1%). 28 (control group), 12 (NDH), and 16 (T2DM) primary care contacts per individual per year were identified, with 27,881, 282,371, and 314,880 inpatient admissions for the control, NDH, and T2DM cohorts, respectively. Prescription of drugs used to treat T2DM in individuals with NDH and T2DM was 27,772 (18.2%) and 109,361 (88.1%), respectively, accounting for approximately one in five individuals with NDH developing T2DM. Conclusion Both NDH and T2DM were associated with significant multimorbidity alongside primary and secondary care utilisation. Given the morbidity highlighted with NDH, we highlight the need for earlier detection of NDH, recognition of multimorbidity associated with both NDH and T2DM, as well as the need for the further implementation of interventions to prevent progression to T2DM/multimorbidity.Keywords
Funding Information
- Department of Global Medical Affairs, AstraZeneca (N/A)
This publication has 18 references indexed in Scilit:
- The prevalence of retinopathy in prediabetes: A systematic reviewSurvey of Ophthalmology, 2022
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th editionDiabetes Research and Clinical Practice, 2019
- The North West London Diabetes Transformation Programme (NWL‐DTP): the journey so far in optimising diabetes care within North West LondonPractical Diabetes, 2019
- A third of adults in England have "prediabetes," study saysBMJ, 2014
- Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011Diabetic Medicine, 2012
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic AdultsNew England Journal of Medicine, 2010
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001